The primary tumor was submitted to cobas<sup>®</sup> EGFR Mutation Test v2 (Roche Diagnostics Ltd.), next generation sequencing (Oncomine Comprehensive Assay v3; Thermo Fisher Scientific), the AmoyDx<sup>®</sup> Essential NGS panel (Amoy Diagnostics, Xiamen, China), all of which were positive for <i>EGFR L858R</i> and <i>de novo T790M</i>. This evidence concerns the gene EGFR and neoplasm.